Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1632 1645 1648 1671 1672
This examiner grants 57% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17934810 | METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß CORONAVIRUS ANTIBODY IN A SAMPLE | Final Rejection | Abbott Laboratories |
| 17783038 | GENE TRANSFER SYSTEM | Non-Final OA | The University of North Carolina at Chapel Hill |
| 18024127 | COVID ASSAY CONTROLS | Non-Final OA | The Regents of the University of California |
| 18108417 | Production of High Titer Recombinant Vesicular Stomatitis Virus in Suspension Cell Culture | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17603302 | MODIFIED AAV VECTORS THAT DAMPEN THE HUMORAL IMMUNE RESPONSE | Final Rejection | University of Florida Research Foundation, Incorporated |
| 17055502 | IN SITU CELL SCREENING METHODS AND SYSTEMS | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 17670091 | PRIMER DESIGN AND USE FOR LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) PATHOGEN DETECTION | Final Rejection | Purdue Research Foundation |
| 18511486 | Minimal Human-Derived Virus-Like Particles and Methods of Use Thereof for Delivery of Biomolecules | Non-Final OA | The General Hospital Corporation |
| 16975541 | NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS HAVING REDUCED CAPSID DEAMIDATION AND USES THEREFOR | Final Rejection | The Trustees of the University of Pennsylvania |
| 18704248 | ONCOLYTIC VIROTHERAPY COMPOSITIONS AND METHODS | Non-Final OA | UNM RAINFOREST INNOVATIONS |
| 17996287 | IDENTIFICATION OF NSP1 GENE AS TARGET OF SARS-COV-2 REAL-TIME RT-PCR USING NANOPORE WHOLE GENOME SEQUENCING | Final Rejection | The University of Hong Kong |
| 17905040 | METHOD FOR PRODUCING INACTIVATED INFLUENZA VACCINE AND VACCINE COMPOSITION THEREOF | Non-Final OA | DENKA COMPANY LIMITED |
| 17108183 | VIRAL VECTOR PURIFICATION APPARATUS AND METHOD | Final Rejection | GLOBAL LIFE SCIENCES SOLUTIONS USA LLC |
| 18014947 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Peptide Epitopes | Non-Final OA | The Brigham and Women`s Hospital, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy